SymbiO2 has developed a proprietary photosynthetic scaffold technology that provides physicians with a novel and effective solution for chronic wounds, which account for US$10B/year. The technology is designed to produce oxygen and wound-healing factors upon exposing the dressing to light. The prototype has been validated in preclinical settings and we plan to obtain FDA 510(k) approval before licensing or seeking M&A possibilities.